Skip to content
10-K

Annual Report

Acurx Pharmaceuticals, Inc. ACXP

0001104659-26-027052

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 12, 2026 2.86M sh
Shares Diluted FY 2025 · Dec 31, 2025 1.5M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 808.17K sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$6.79M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$10.38M
Stockholders Equity FY 2025 · Dec 31, 2025 $5.27M
Stockholders Equity FY 2025 · Dec 31, 2024 $615.12K
Stockholders Equity FY 2025 · Dec 31, 2023 $4.67M
Current Liabilities FY 2025 · Dec 31, 2025 $2.42M
Current Liabilities FY 2025 · Dec 31, 2024 $3.24M
Total Liabilities FY 2025 · Dec 31, 2025 $2.42M
Total Liabilities FY 2025 · Dec 31, 2024 $3.24M
Total Assets FY 2025 · Dec 31, 2025 $7.69M
Total Assets FY 2025 · Dec 31, 2024 $3.86M
Eps Diluted FY 2025 · Dec 31, 2025 −$5.32
Eps Diluted restated FY 2025 · Dec 31, 2024 −$17.45
Eps Basic FY 2025 · Dec 31, 2025 −$5.32
Eps Basic restated FY 2025 · Dec 31, 2024 −$17.45
Rd Expense FY 2025 · Dec 31, 2025 $1.83M
Rd Expense FY 2025 · Dec 31, 2024 $5.4M
Net Income FY 2025 · Dec 31, 2025 −$7.97M
Net Income FY 2025 · Dec 31, 2024 −$14.1M
Operating Income FY 2025 · Dec 31, 2025 −$8.09M
Operating Income FY 2025 · Dec 31, 2024 −$14.12M